Petrylak, DP, de Wit, R, Chi, KN, Drakaki, A, Sternberg, CN, Nishiyama, H, Castellano, D, Hussain, SA, Fléchon, A, Bamias, A, Yu, EY
, van der Heijden, MS, Matsubara, N, Alekseev, B, Necchi, A, Géczi, L, Ou, Y-C, Coskun, HS, Su, W-P, Bedke, J, Gakis, G, Percent, IJ, Lee, J-L, Tucci, M, Semenov, A, Laestadius, F, Peer, A, Tortora, G, Safina, S, Garcia del Muro, X, Rodriguez-Vida, A, Cicin, I, Harputluoglu, H, Tagawa, ST, Vaishampayan, U, Aragon-Ching, JB, Hamid, O, Liepa, AM, Wijayawardana, S, Russo, F, Walgren, RA, Zimmermann, AH, Hozak, RR, Bell-McGuinn, KM, Powles, T, Wong, S-LS, Tan, TH, Hovey, EJ, Clay, TD, Wan Ng, SS, Rutten, A, Machiels, J-P, Dumez, H, Cheng, SY-S, Ferrario, C, Sengeloev, L, Jensen, NV, Thibault, C, Laguerre, B, Joly, F, Culine, S, Becht, C, Niegisch, GN, Stöckle, M, Grimm, M-O, Schwentner, CA, Schultze-Seemann, W, Kalofonos, H, Mavroudis, D, Papandreou, C, Karavasilis, V, Révész, J, Rosenbaum, E, Leibowitz-Amit, R, Kejzman, D, Sarid, D, Scagliotti, GV, Bracarda, S, Massari, F, Osawa, T, Miyajima, N, Shinohara, N, Fukuta, F, Ohyama, C, Obara, W, Yamashita, S, Tomita, Y, Kawai, K, Fukasawa, S, Oyama, M, Yonese, J, Nagata, M, Uemura, M, Nishimura, K, Kawakita, M, Tsunemori, H, Hashine, K, Inokuchi, J, Yokomizo, A, Nagamori, S, Lee, HJ, Park, SH, Rha, SY, Kim, YJ, Lee, Y-G, Vazquez Cortés, L, Lorena Urzua Flores, C, Blaisse, RJB, Erdkamp, FLG, Aarts, MJB, Wojcik-Tomaszewska, J, Tomczak, P, Sikora-Kupis, B, Schenker, M, Herzal, AA, Udrea, AA, Karlov, P, Fomkin, R, Gajate Borau, P, Grande, E, Delgado Mignorance, JI, Su, Y-L, Li, J-R, Lin, C-L, Lin, C-C, Yeh, S-P, Erman, M, Urun, Y, Golovko, Y, Bondarenko, I, Sinielnikov, I, Crabb, SJ, Syndikus, I, Huddart, R, Sundar, S, Chowdhury, S, Sarwar, N, Flaig, TW, Pan, CX, Schwarz, JK, Cultrera, JL, Acs, PI, Hainsworth, JD, Herms, BT, Lawler, WE & Lowe, TE 2020, '
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial',
lancet oncology, vol. 21, no. 1, pp. 105-120.
https://doi.org/10.1016/S1470-2045(19)30668-0